Skip to main content

Table 1 PROWESS and ENHANCE patient baseline characteristics

From: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

Variable PROWESS ENHANCE
  Placebo (n = 840) DrotAA (n = 850) DrotAA (n = 2378)
Sex (% male [n]) 58.0 (487) 56.1 (477) 58.2 (1383)
Mean age (years [SD]) 60.6 (16.5) 60.5 (17.2) 59.1 (16.9)
Caucasian (% [n]) 82.0 (689) 81.8 (695) 90.6 (2154)
APACHE II score (mean [SD]) 25.0 (7.8) 24.6 (7.6) 22.0 (7.4)
SOFA score (mean [SD])    
   Cardiovascular 2.7 (1.5) 2.6 (1.5) 3.0 (1.4)
   Respiratory 2.7 (1.1) 2.7 (1.0) 2.7 (1.0)
   Renal 1.1 (1.1) 1.1 (1.1) 1.3 (1.2)
   Hematologic 0.7 (1.0) 0.7 (0.9) 0.8 (1.0)
   Hepatic 0.6 (0.9) 0.6 (0.8) 0.7 (0.9)
Protein C (median [IQR]) 50 (33 to 68) 47 (30 to 63) 45 (30 to 64)
Protein S (median [IQR]) 38 (23 to 58) 35 (33 to 57) -
Antithrombin III (median [IQR]) 60 (45 to 75) 58 (43 to 74) -
Interleukin-6 (median [IQR]) 484 (129 to 2539) 496 (153 to 2701) -
Prothrombin time (median [IQR]) 18.6 (16.4 to 21.8) 18.7 (16.6 to 22.1) -
D-dimer (median [IQR]) 4.1 (2.2 to 8.7) 4.2 (2.3 to 8.1) -
  1. APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrecogin alfa (activated); ENHANCE, Extended Evaluation of Recombinant Activated Protein C; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; SD, standard deviation; SOFA, Sequential Organ Failure Assessment; IQR, interquartile range.